JP2009537624A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537624A5
JP2009537624A5 JP2009511581A JP2009511581A JP2009537624A5 JP 2009537624 A5 JP2009537624 A5 JP 2009537624A5 JP 2009511581 A JP2009511581 A JP 2009511581A JP 2009511581 A JP2009511581 A JP 2009511581A JP 2009537624 A5 JP2009537624 A5 JP 2009537624A5
Authority
JP
Japan
Prior art keywords
abu
cbp
contrast agent
peptide
ily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009511581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537624A (ja
Filing date
Publication date
Priority claimed from GBGB0610395.6A external-priority patent/GB0610395D0/en
Application filed filed Critical
Publication of JP2009537624A publication Critical patent/JP2009537624A/ja
Publication of JP2009537624A5 publication Critical patent/JP2009537624A5/ja
Ceased legal-status Critical Current

Links

JP2009511581A 2006-05-25 2007-05-25 新規造影剤 Ceased JP2009537624A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0610395.6A GB0610395D0 (en) 2006-05-25 2006-05-25 Novel imaging agents
PCT/GB2007/001964 WO2007138291A2 (en) 2006-05-25 2007-05-25 Novel imaging agents

Publications (2)

Publication Number Publication Date
JP2009537624A JP2009537624A (ja) 2009-10-29
JP2009537624A5 true JP2009537624A5 (enExample) 2010-06-17

Family

ID=36687722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511581A Ceased JP2009537624A (ja) 2006-05-25 2007-05-25 新規造影剤

Country Status (8)

Country Link
US (1) US8304388B2 (enExample)
EP (1) EP2026844A2 (enExample)
JP (1) JP2009537624A (enExample)
CN (1) CN101454026B (enExample)
BR (1) BRPI0711937A2 (enExample)
GB (1) GB0610395D0 (enExample)
RU (1) RU2441668C2 (enExample)
WO (1) WO2007138291A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224959B1 (en) * 2007-12-13 2015-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
DK2280720T3 (en) * 2008-03-27 2019-06-11 Purdue Research Foundation COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, MANUFACTURING AND PROCEDURE FOR USE
JP2010215572A (ja) * 2009-03-17 2010-09-30 Japan Health Science Foundation 歯髄炎診断マーカー及び歯髄炎診断システム
WO2011128931A1 (ja) * 2010-04-12 2011-10-20 財団法人ヒューマンサイエンス振興財団 歯髄炎診断マーカー及び歯髄炎診断システム
WO2012112767A2 (en) * 2011-02-16 2012-08-23 Purdue Research Foundation Collagen-targeted nanoparticles
HUE031596T2 (en) 2011-05-24 2017-07-28 Symic Ip Llc Synthetic peptidoglycans that bind hyaluronic acid, their production and use
WO2014055253A1 (en) * 2012-10-04 2014-04-10 The General Hospital Corporation Methods of synthesizing and using peg-like fluorochromes
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
BR112015022917A2 (pt) 2013-03-15 2017-07-18 Symic Biomedical Inc peptidoglicanos sintéticos componentes da matriz extracelular
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
WO2016123570A1 (en) 2015-01-30 2016-08-04 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of using
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3445402A4 (en) * 2016-04-21 2019-12-11 The Board Of Regents Of The University Of Texas System METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS
EP3648774A4 (en) 2017-07-07 2021-04-21 Symic IP, LLC SYNTHETIC BIOCONJUGATES
JP7174429B2 (ja) * 2017-08-31 2022-11-17 学校法人早稲田大学 コラーゲンへの結合活性を有する環状ペプチド
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
CA2117780A1 (en) * 1992-04-10 1993-10-28 Paul F. Goetinck Cartillage matrix protein and methods for use
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0327494D0 (en) * 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
CA2575416A1 (en) 2004-02-27 2005-09-09 The University Of Western Ontario Bone sialoprotein collagen-binding peptides
US7575738B2 (en) * 2004-08-13 2009-08-18 General Electric Company Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
BRPI0518328A2 (pt) * 2004-11-22 2008-11-11 Ge Healthcare As agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica

Similar Documents

Publication Publication Date Title
JP2009537624A5 (enExample)
JP5784911B2 (ja) ボンベシンアナログペプチドアンタゴニスト複合体
RU2008146031A (ru) Новые визуализирующие агенты
JP6824738B2 (ja) 放射性トレーサー組成物及び方法
CN111183146A (zh) 高亲和力选择性结合cxcr4的缀合物及其使用方法
EP3956346A1 (en) Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
KR20140012112A (ko) 테크네튬 표지화 펩티드
JP2019196356A (ja) 精製方法及び組成物
JP6231882B2 (ja) 放射性コンジュゲーション方法
KR102046437B1 (ko) 방사성불소화 방법
CA3236432A1 (en) Gastric inhibitory peptide receptor ligands
JP6574997B2 (ja) 金属錯体とそのフッ素化
JP2006508084A (ja) Tc錯体と標的部分との複合体並びにMRI診断での使用
CN117396491A (zh) 基于肽的新型诊断剂和治疗剂
JP2016532700A (ja) 放射性標識方法
JP2015086213A (ja) 放射性核種標識オクトレオチド誘導体
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
CN117320759A (zh) 放射性药物生长抑素受体配体及其前体
CN114845742A (zh) 用于癌症成像和治疗的经改性的grpr拮抗剂肽
CN108697767A (zh) 包含用于成像目的的螯合部分的选择性胰高血糖素受体激动剂
CN105339013A (zh) 金属络合物及其氟化
CN104854126A (zh) 多肽及成像方法
CN121712789A (zh) Fap靶向环肽及其缀合物
CN119630622A (zh) 用于放射性药物的硅系氟化物受体基团
WO2014096191A1 (en) Bis 2h-imidazole-2-thione chelating agents as ligands for radiopharmaceutical in vivo imaging